AstraZeneca India to sell 64-acre Bengaluru site for ₹3,400 Cr
Representative AI image BENGALURU: AstraZeneca’s Indian arm plans to sell its 64-acre manufacturing facility in North Bengaluru as part of a review of its global supply and manufacturing network by its UK-based parent company. The land, estimated to garner around ₹3,400 crore for AstraZeneca Pharma India, has attracted interest from developers such as Sattva Group, Aurobindo Pharma, and RMZ. This sale is part of a broader land monetization initiative. A source indicated, “AstraZeneca has shortlisted three potential bidders and plans to finalize the deal soon.” The land, located in a prime area of North Bengaluru, is valued at over ₹53…